Cochrane · systematic review · CD009913
Fixed‐dose combinations of drugs versus single‐drug formulations for treating pulmonary tuberculosis
Gallardo, CR, Rigau Comas, D, Valderrama Rodríguez, A, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
Infectious DiseasesAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
7
current version
GRADE rated
6
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 1 · 14.3%Very low 0 · 0%Low 2 · 28.6%Moderate 3 · 42.9%High 1 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
'Summary of findings' table 1
Population: treating pulmonary TB
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Treatment failure | RR 1.28 [0.82, 2] | 7 studies · 3606 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Relapse | RR 1.28 [1, 1.64] | 10 studies · 3621 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Death | RR 0.96 [0.67, 1.39] | 11 studies · 4800 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Sputum smear or culture conversion at end of treatment | RR 0.99 [0.96, 1.02] | 7 studies · 2319 participants | High |
Serious adverse events | RR 1.45 [0.9, 2.33] | 6 studies · 3388 participants | Moderate Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Adverse events leading to discontinuation of therapy | RR 0.96 [0.56, 1.66] | 13 studies · 5530 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Combined endpoint of treatment failure, relapse, or death** | no estimate extracted | 0 studies · 0 participants | Ungraded |